Drug Approval | December 13, 2022
European Commission approves SPEVIGO for generalized pustular psoriasis flares
EC grants conditional marketing authorization based on the EFFISAYIL trial
EC grants conditional marketing authorization based on the EFFISAYIL trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Subscribe To Our Newsletter & Stay Updated
